Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of MD1003 (high-dose biotin) in spinal progressive multiple sclerosis
2013-002113-35Phase 3Completed
- Sponsor
- MedDay Pharmaceuticals
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of biotin in multiple sclerosis (MS) (3 arms), sponsored by MedDay Pharmaceuticals. Primary endpoint: Clinical improvement at 12 months. Started May 2015; status: completed.
02
Drugs
biotin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-002113-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002113-35.